LYPE:XETRA:XETRA-Lyxor MSCI World Health Care TR UCITS ETF - C-EUR EUR (EUR)

ETF | Others |

Last Closing

USD 480.7

Change

0.00 (0.00)%

Market Cap

USD 0.78B

Volume

582.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.05 (-0.10%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.07%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.09 (-0.32%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.07 (+0.23%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.08 (-0.32%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.29 (-0.62%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

+0.82 (+0.58%)

USD 102.09B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.03 (-0.06%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.59 (+0.56%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.26 (+0.53%)

USD 80.38B

ETFs Containing LYPE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.71% 78% C+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.71% 78% C+ 75% C
Trailing 12 Months  
Capital Gain 6.01% 35% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.01% 34% F 39% F
Trailing 5 Years  
Capital Gain 55.69% 77% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.69% 75% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 11.26% 70% C- 68% D+
Dividend Return 11.26% 69% C- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.20% 65% D 72% C
Risk Adjusted Return 122.35% 99% N/A 99% N/A
Market Capitalization 0.78B 73% C 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike